TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04171713

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion + Treatment as usual
Description: Structured and developed over eight weeks (8 sessions), participants meet weekly for an average of 2 hours to experience the techniques and conceptual learning about mindfulness and can be adapted to one or 1.5 hour sessions. to be applicable within the contexts of health, education, and organizations. Plus participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attachment-based compassion therapy + Treatment as usual
Description: It is a program based on one of the fundamental psychological constructs that explain individuals' interpersonal relationships, attachment styles. It lasts 8 weeks in which participants meet for 2 or 2.5 hours at each meeting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: participation in support groups offered by the bariatric surgery clinic with capacity for 40 participants, monthly attendance and duration of 2 hours. In these meetings, there is always the presence of a surgeon, a psychologist and another invited professional (endocrinologist, nutritionist, speech therapist or dentist), who give a thematic lecture and then there is the opening space for doubts and exchange of experiences.
Study: NCT02156921

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: App-based training
Study: NCT05093465

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Intervention
Description: Participants were provided with sleep hygiene and stimulus control procedure plus procedures to reduce technology usage in bed (i.e., technology usage stimulus control).~In addition to the sleep hygiene and stimulus control procedures, participants were also given a set of procedures aimed at changing technology usage behavior at bedtime and throughout the day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Participants were provided with sleep hygiene and stimulus control procedures.
Study: NCT04153448

Intervention type: OTHER
Intervention: Measurement of functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test

Intervention type: OTHER
Intervention: Measurement of functional capacity
Description: Functional capacity of participants will be measured with six-minute walk test and sit-to-stand test
Study: NCT03629028

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Residual myometrium thickness
Description: The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Residual myometrium thickness
Description: The myometrium will be closed by single or double layer during cesarean and residual myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Niche Presence
Description: The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Niche Presence
Description: The myometrium will be closed by single or double layer during cesarean and niche presence will be evaluated in 6 to 9 months by saline infusion sonography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Adjacent myometrium thickness
Description: The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Adjacent myometrium thickness
Description: The myometrium will be closed by single or double layer during cesarean and adjacent myometrium thickness will be evaluated in 6 to 9 months by saline infusion sonography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Niche Measurements (depth of niche, width of niche, length of niche)
Description: The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Niche Measurements (depth of niche, width of niche, length of niche)
Description: The myometrium will be closed by single or double layer during cesarean and three dimensional niche measurements will be evaluated in 6 to 9 months by saline infusion sonography.
Study: NCT06616428

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bike group fitness class
Description: Comprised a rhythmic indoor cycling session, characterized by fluctuations in intensity corresponding to changes in position, music rhythm, cadence, and revolutions per minute. Participants were instructed to strictly follow verbal cues from the instructor, adjusting cycling cadence and resistance as directed, for 45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pump Power
Description: Entails a comprehensive total-body weight-training program with a focus on improving strength, muscular endurance, and overall fitness of large muscle groups. The class, choreographed to music, involved participants performing a combination of barbell, body-weight exercises, and free-weight plates, during 45 minutes. Participants selected weights based on the target muscle group for the specific song or track and their individual fitness goals.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Global Training
Description: Incorporated both aerobic and resistance components, combining athletic movements like running, lunging, and jumping with strength exercises such as barbells, body-weight exercises, and free-weight plates for the large muscle groups, during 45 minutes.
Study: NCT00940602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredients used as a placebo comparator, provided as 125 mg, 250 mg, and 500 mg dispersible tablets for oral use
Study: NCT01816984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Given PO
Study: NCT02034604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Study: NCT04068311

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geriatric Screening tools
Description: Lean Six Sigma implementation in the Emergency Department of nurse-driven geriatric screening tools and protocols for patients with fall risk, delirium, and high risk scores.
Study: NCT03758430

Intervention type: OTHER
Intervention: Meal-Tagging App
Description: Meal tagging app to capture frequently eaten meals and test meals for 16 weeks.
Study: NCT03255096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6870810
Description: RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
Study: NCT03758430

Intervention type: DEVICE
Intervention: Fitness Tracker
Description: Fitness tracker will be worn around the clock for 16 weeks.
Study: NCT03280641

Intervention type: DRUG
Intervention: Dabigatran Etexilate 110mg
Description: Dabigatran Etexilate 110mg, BID

Intervention type: DRUG
Intervention: Warfarin Sodium
Description: Target INR:1.6-3.0
Study: NCT02367534

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical vein catheterization
Description: A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
Study: NCT01412658

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hydrolyzed milk protein mixture
Description: Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Glycerol placebo
Description: Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.~A food diary is maintained daily.
Study: NCT01838967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - V - C+V
Description: Drug will be administered to according to C - V - C+V sequence for 3 period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C - C+V - V
Description: Drug will be administered to according to C - C+V - V sequence for 3 period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V - C - C+V
Description: Drug will be administered to according to V - C - C+V sequence for 3 period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V - C+V - C
Description: Drug will be administered to according to V - C+V - C sequence for 3 period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C+V - C - V
Description: Drug will be administered to according to C+V - C - V sequence for 3 period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C+V - V - C
Description: Drug will be administered to according to C+V - V - C sequence for 3 period.
Study: NCT02049749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate CARE
Description: CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
Study: NCT01606761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirukumab
Description: Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
Study: NCT02756650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: 150 mg or 300 mg of canakinumab was administered monthly. IV (SC after month 6)
Study: NCT03258346

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Inertial Load Cycling Training
Description: Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inertial Load Cycling Training
Description: Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate Juice
Description: Subjects will consume 8oz of pomegranate juice daily for duration of study.
Study: NCT03255096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab intravenously (IV) at dose of 375 mg/m\^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
Study: NCT03774459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose ANAVEX2-73
Description: Active oral capsule
Study: NCT01816984

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study: NCT01469260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedometer
Description: Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
Study: NCT03443817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele rehab
Description: Video Consultation (VC) Sessions: Each patient will have the opportunity to have minimum one VC per week the first month, one VC each second week the second month one VC a month~Retraining breath: Patients will also be instructed to use different techniques to breath during the video consultations with the physiotherapist.~Chat Sessions: Each patient has the opportunity to chat with the physiotherapist any time via the chat module of the system.~Workout Sessions with a Virtual Physiotherapist Agent (VPA): The patient will train according to what is decided by the physiotherapist and the patient in the VC or chat meetings. Normally, the patients will train 10-20 minutes daily at home with its individual and tailored VPA.~Patients' security: In order to minimize the risks of possible accidents while performing the exercises, the patient will answer questions before and after each exercise performance that the physiotherapist can follow in real time.
Study: NCT01854528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267, ABT-333
Description: Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
Study: NCT00521989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/90)
Description: CRx-102 dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/90)
Description: CRx-102 dose 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/180)
Description: CRx-102 dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRx-102 (2.7/360)
Description: CRx-102 dose 3
Study: NCT00882206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: At baseline when peripheral blood draw and bone marrow aspirate performed.~\*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Days 1-4, 15 mg/m\^2 intravenously (IV) over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Day 5, 60 mg/m\^2 intravenously (IV) over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age \<18 years and 400 mg orally every day for \>18 years on Days 5-33.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: \*\*Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: 2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 40mg/m2/day divided BID (days 5 - 33)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
Study: NCT01854528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon a-2a (PegINF)
Description: Pre-filled syringe

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telaprevir
Description: Film-coated tablet
Study: NCT03774459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mid dose ANAVEX2-73
Description: Active oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule
Study: NCT00874601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diovan® (valsartan)
Description: The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.~In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded.
Study: NCT03830437

Intervention type: OTHER
Intervention: Evaluation of newborn stress
Description: Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.

Intervention type: OTHER
Intervention: Evaluation of newborn stress
Description: Newborn stress will be evaluated by salivary cortisol levels at 48 hr of life. Saliva sample of the newborns will be collected in oral cavity at 48 hr of life. Samples collected will be storage at -80 C for up to 4 months and analysed by analysis laboratory of Poliambulanza Foundation.

Intervention type: OTHER
Intervention: Evaluation of body weight trend
Description: Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life

Intervention type: OTHER
Intervention: Evaluation of body weight trend
Description: Body weight trend between newborns subjected to double weighing or to body weight control will be carried out at 36 hr and 48 hr of life
Study: NCT01696643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-5945

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02337569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-02

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT03146065

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06730512
Description: Comparison of different dosages of PF-06730512 to Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparison of Placebo to different doses of PF-06730512